Chagas disease future or investigational therapies

Jump to: navigation, search

Chagas disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Chagas disease from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

The heart in Chagas' disease

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chagas disease future or investigational therapies On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chagas disease future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chagas disease future or investigational therapies

CDC on Chagas disease future or investigational therapies

Chagas disease future or investigational therapies in the news

Blogs on Chagas disease future or investigational therapies

Directions to Hospitals Treating Chagas disease

Risk calculators and risk factors for Chagas disease future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.

Overview

Although novel investigational drugs are being studied for chronic Chagas disease, to date no new pharmacologic therapy has proven to be effective compared with the current standard of care (benznidazole therapy)

Investigational Therapies

  • Clinical trials that evaluate the efficacy of novel investigational therapies for chronic Chagas disease are scarce, primarily because it has been difficult for researchers to define efficacy endpoint in clinical trials in the past.[1]
  • The introduction of PCR results for the evaluation of drug success has been useful for the study of novel investigational drugs
  • The following investigational drugs have been studied. Although the drugs were associated with high rates of negative PCR successful results immediately post-treatment, long-term follow-up demonstrated that the majority of patients who received those drugs relasped with positive PCR results.[1]
  • Posaconazole - Patients in the posaconazole arm had a significantly higher rate of positive PCR during 12-month follow-up compared with the benznidazole arm.[1]
  • Ravuconazole - Patients in the ravuconazole arm had a significantly higher rate of positive PCR during 12-month follow-up compared with the benznidazole arm.[1]

References

  1. 1.0 1.1 1.2 1.3 Bern C (2015). "Chagas' Disease". N Engl J Med. 373 (5): 456–66. doi:10.1056/NEJMra1410150. PMID 26222561.

Linked-in.jpg